Inter Parfums
This article was originally published in The Rose Sheet
Executive Summary
Fragrance manufacturer improves 2003 financial outlook, with sales now expected to reach $182 mil. on growth of prestige fragrances and initial sales of Burberry Brit, firm says. Estimate is up from previous projection of $177 mil.-$179 mil. (1"The Rose Sheet" Oct. 13, 2003, In Brief). Net income is expected to be $13.4 mil. for the year, versus prior estimate of $12.7 mil.-$12.9 mil. Inter Parfums 2004 sales are projected to be about $206 mil., with net income of approximately $15 mil., assuming the dollar remains at current levels, company says...
You may also be interested in...
Inter Parfums preclose Q3
Firm's 2003 sales will top $177 mil.-$179 mil., representing a 36%-37% gain over 2002, if the dollar remains at current levels, Inter Parfums says in Oct. 9 third quarter sales and earnings preannouncement. Forecast is up from earlier projected sales of $165 mil.-$168 mil. Net income expected to jump 35%-37% to $12.7 mil.-$12.9 mil., company says. Inter Parfums also predicts aggregate third quarter sales will reach $57 mil., up 53% over the prior-year period. Firm attributes improved performance to launches of Burberry Brit, Diane von Furstenberg Beauty (1"The Rose Sheet" June 23, 2003, p. 6 and 2"The Rose Sheet" June 2, 2003, p. 11). Final Q3 results will be reported Nov. 3...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.